Risk of adverse events with fibrates.
An increased risk for adverse events was observed with gemfibrozil relative to fenofibrate, predominantly driven by an increased rate of rhabdomyolysis. This difference was especially noticeable in patients taking the combination of gemfibrozil and a statin, particularly cerivastatin.
Molecular Cardiology Research Institute, Department of Medicine, Division of Cardiology, Tufts-New England Medical Center and Tufts University School of Medicine, Boston, Massachusetts 02111, USA.
Alawi A
AA
Alsheikh-Ali
Jeffrey T
JT
Kuvin
Richard H
RH
Karas
D000368:Aged; D056486:Chemical and Drug Induced Liver Injury; D005260:Female; D011345:Fenofibrate / Q000009:adverse effects*; D015248:Gemfibrozil / Q000009:adverse effects; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy; D000960:Hypolipidemic Agents / Q000009:adverse effects*; D008107:Liver Diseases / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D012206:Rhabdomyolysis / Q000139:chemically induced* / Q000453:epidemiology*; D012307:Risk Factors; D017211:Treatment Failure; D014481:United States / Q000453:epidemiology
D000960:Hypolipidemic Agents; D015248:Gemfibrozil; D011345:Fenofibrate